Humoral response to SARS-CoV-2 mRNA vaccine in patients with multiple sclerosis treated with natalizumab

Autor:	Federica Giuliano, Mario Risi, Giovanna Donnarumma, Antonio Gallo, Gioacchino Tedeschi, Massimiliano Galdiero, Riccardo Maria Borgo, Alessandro d’Ambrosio, Rocco Capuano, Nicola Coppola, Alvino Bisecco, Manuela Altieri, Federica Matrone, Miriana Conte, Elena Grimaldi
Přispěvatelé:	Capuano, R., Donnarumma, G., Bisecco, A., Grimaldi, E., Conte, M., D'Ambrosio, A., Matrone, F., Risi, M., Borgo, R. M., Altieri, M., Giuliano, F., Coppola, N., Galdiero, M., Tedeschi, G., Gallo, A.
Jazyk:	angličtina
Rok vydání:	2021
Předmět:	Pharmacology Neurology in the Time of COVID-19 2019-20 coronavirus outbreak Messenger RNA Coronavirus disease 2019 (COVID-19) business.industry Multiple sclerosis Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) medicine.disease Virology Natalizumab Neurology Medicine In patient Neurology. Diseases of the nervous system Neurology (clinical) RC346-429 business Letter to the Editor medicine.drug
Zdroj:	Therapeutic Advances in Neurological Disorders Therapeutic Advances in Neurological Disorders, Vol 14 (2021)
ISSN:	1756-2864 1756-2856
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01bdb7cab029941a7acf7d035fb66eca http://europepmc.org/articles/PMC8369851 Zobrazit plný text záznamu